Paying for Prescription Drugs in the New Administration | Clinical Pharmacy and Pharmacology | JAMA jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.
No Hotter Health Care Issue Than Drug Pricing, Lobbyist Says
Legislation on prescription drugs could move quicker than other issues, a consultant told NAHU members Monday.
There is no health care issue hotter than drug pricing, Jonathon Jones told members of the National Association of Health Underwriters at their virtual Capitol Conference. Jones is a partner with the government relations consultant Peck Madigan Jones.
“It’s not just a Democratic priority – it has become a priority for both parties,” Jones said in looking ahead to what the Biden administration and the new Congress mean for health care.
Of the major health care issues in Washington, lowering the cost of prescription drugs is the issue that enjoys the most bipartisan support, at least ideologically, Jones said. “Everyone agrees on the idea that we need to do something to change the U.S. laws to reduce drug prices.”
Big Pharma mergers and acquisitions destroy industry innovation and harm patients naturalnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from naturalnews.com Daily Mail and Mail on Sunday newspapers.
Millions of Americans can’t afford the drugs they need to survive. It’s well past time for Congress to come to their rescue. Using budget reconciliation now is Democrats’ chance to be the champions the American public needs.
By Ed Schoonveld Feb. 2, 2021Reprints
Adobe
As the Biden administration assumes leadership in Washington and former President Donald Trump’s most-favored nation ruling has been halted by a federal judge, drug price controls don’t feel imminent.
Though this should provide some relief to the R&D-based biopharmaceutical industry, the relief may be short-lived. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED
What is it? STAT+ is STAT s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.